GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nykode Therapeutics AS (OSL:NYKD) » Definitions » Selling, General, & Admin. Expense

Nykode Therapeutics AS (OSL:NYKD) Selling, General, & Admin. Expense : kr0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nykode Therapeutics AS Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Nykode Therapeutics AS's selling, general, & admin. expense for the three months ended in Sep. 2024 was kr0.00 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.00 Mil.


Nykode Therapeutics AS Selling, General, & Admin. Expense Historical Data

The historical data trend for Nykode Therapeutics AS's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nykode Therapeutics AS Selling, General, & Admin. Expense Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 10.06 74.52 83.37 87.85 66.23

Nykode Therapeutics AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nykode Therapeutics AS's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Nykode Therapeutics AS's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nykode Therapeutics AS's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Selling, General, & Admin. Expense falls into.



Nykode Therapeutics AS Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nykode Therapeutics AS  (OSL:NYKD) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Nykode Therapeutics AS Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Nykode Therapeutics AS's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Nykode Therapeutics AS Business Description

Industry
Traded in Other Exchanges
Address
Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.

Nykode Therapeutics AS Headlines

No Headlines